TrialBritish journal of clinical pharmacology2020

Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions.

Melanie Rijsbergen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.